Carlos J. Diaz-Almeciga
Bogota, DC, Colombia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
Modeling Tay-Sachs Disease in Astrocyte-like Cells Reveals Significant Changes in the Transcriptomic Profile.
Journal: International journal of molecular sciences
Published: May 28, 2026
Evaluation of GlcNAc-Configured Glycomimetics as Pharmacological Chaperones of NAGLU for the Treatment of Mucopolysaccharidosis IIIB.
Journal: Biomolecules
Published: December 20, 2025
Yeast-Produced Human Recombinant Lysosomal β-Hexosaminidase Efficiently Rescues GM2 Ganglioside Accumulation in Tay-Sachs Disease.
Journal: Journal of personalized medicine
Published: March 23, 2025
Evaluation of the PP6D5 Polymer as a Novel Non-Viral Vector in the Development of a CRISPR/nCas9-Based Gene Therapy for Tay-Sachs Disease.
Journal: Pharmaceutics
Published: March 21, 2025
CRISPR/nCas9-Edited CD34+ Cells Rescue Mucopolysaccharidosis IVA Fibroblasts Phenotype.
Journal: International journal of molecular sciences
Published: March 19, 2025
Study of Potential Blocking Peptides Targeting the SARS-CoV-2 RBD/hACE2 Interaction.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: September 02, 2024
Identification of Orthosteric and Allosteric Pharmacological Chaperones for Mucopolysaccharidosis Type IIIB.
Journal: Chembiochem : a European journal of chemical biology
Published: January 29, 2024
Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks.
Journal: International journal of molecular sciences
Published: October 18, 2023
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.
Journal: Heliyon
Published: October 12, 2023
Iron oxide-coupled CRISPR-nCas9-based genome editing assessment in mucopolysaccharidosis IVA mice.
Journal: Molecular therapy. Methods & clinical development
Published: August 24, 2023
Last Updated: 09/26/2026